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Introduction
Healthcare decision making is complex. Decision-mak-
ing processes and the factors (criteria) that decision mak-
ers should consider vary for different types of decisions, 
including clinical recommendations, coverage decisions, 
and health system or public health recommendations or 
decisions.1-4 However, some criteria are relevant for all of 
these decisions, including the anticipated effects of the 
options being considered, the certainty of the evidence 
for those effects (also referred to as quality of evidence or 
confidence in effect estimates), and the costs and feasi-
bility of the options. Decision makers must make judg-
ments about each relevant factor, informed by the best 
evidence that is available to them.
Often, the processes that decision makers use, the cri-
teria that they consider and the evidence that they use to 
reach their judgments are unclear.5-8 They may omit 
important criteria, give undue weight to some criteria, or 
not use the best available evidence. Systematic and 
transparent systems for decision making can help to 
ensure that all important criteria are considered and that 
the best available research evidence informs decisions.
Clinicians depend on clinical practice guidelines. Rig-
orously developed guidelines synthesise the available 
relevant research, facilitating the translation of evi-
dence into recommendations for clinical practice.9 
 However, the quality of guidelines is often  suboptimal.10 11 
If guidelines are not developed systematically and trans-
parently, clinicians are not able to decide whether to rely 
on them or to explore disagreements when faced with 
conflicting recommendations.12
The GRADE (Grading of Recommendations Assess-
ment, Development and Evaluation) Working Group 
has previously developed and refined a system to assess 
the certainty of evidence of effects and strength of rec-
ommendations.13-15 More than 100 organisations glob-
ally, including the World Health Organization, the 
Cochrane Collaboration, and the National Institute for 
Health and Care Excellence (NICE) now use or have 
adopted the principles of the GRADE system. Recently, 
through the DECIDE (Developing and Evaluating Com-
munication Strategies to Support Informed Decisions 
and Practice Based on Evidence) project (http://www.
decide-collaboration.eu),16  funded by the European 
Union, the GRADE Working Group has developed the 
Evidence to Decision (EtD) frameworks to support the 
process of moving from evidence to decisions. We have 
developed EtD frameworks for making clinical recom-
mendations, coverage decisions, and health system or 
public health recommendations and decisions. The 
frameworks build on the GRADE approach to assessing 
the strength of recommendations.17-19
We developed EtD frameworks using an iterative 
process that is described in the project protocol.16 
The starting point for EtD frameworks was the 
GRADE Working Group’s approach for moving from 
evidence to clinical recommendations.17-19  We itera-
tively  developed the frameworks based on reviews of 
relevant  literature,1-4  brainstorming, feedback from 
 stakeholders,20 application of EtD frameworks to a 
variety of recommendations and decisions, and user 
testing. We strove for consistency across EtD frame-
works for different types of decisions, but, because of 
differences in the nature of the decisions, there are 
some differences in the frameworks. In appendix 1, 
we have provided a glossary of terms used in EtD 
frameworks, including certainty of the evidence, 
decisions, recommendations, and strength of 
 recommendations.
This series of two articles describing the EtD frame-
works is targeted at guideline developers and users of 
guidelines. This first article introduces the frameworks. 
It describes their purpose, development, and structure. 
It also describes how different organisations can adapt 
the frameworks to their own contexts and deci-
sion-making processes. The second article presents the 
framework for clinical recommendations.21
Summary poIntS
•	 Clinicians,	guideline	developers,	and	policymakers	sometimes	neglect	important	
criteria,	give	undue	weight	to	criteria,	and	do	not	use	the	best	available	evidence	
to	inform	their	judgments
•	 Explicit	and	transparent	systems	for	decision	making	can	help	to	ensure	that	all	
important	criteria	are	considered	and	that	decisions	are	informed	by	the	best	
available	research	evidence
•	 The	purpose	of	Evidence	to	Decision	(EtD)	frameworks	is	to	help	people	use	
evidence	in	a	structured	and	transparent	way	to	inform	decisions	in	the	context	of	
clinical	recommendations,	coverage	decisions,	and	health	system	or	public	
health	recommendations	and	decisions
•	 EtD	frameworks	have	a	common	structure	that	includes	formulation	of	the	
question,	an	assessment	of	the	evidence,	and	drawing	conclusions,	though	there	
are	some	differences	between	frameworks	for	each	type	of	decision	
•	 EtD	frameworks	inform	users	about	the	judgments	that	were	made	and	the	
evidence	supporting	those	judgments	by	making	the	basis	for	decisions	
transparent	to	target	audiences
•	 EtD	frameworks	also	facilitate	dissemination	of	recommendations	and	enable	
decision	makers	in	other	jurisdictions	to	adopt	recommendations	or	decisions,	
or	adapt	them	to	their	context
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purpose of the frameworks
The main purpose of the EtD frameworks is to help 
groups of people (panels) use evidence in a structured 
and transparent way to inform decisions in the context 
of clinical recommendations, coverage decisions, and 
health system or public health recommendations and 
decisions.
EtD frameworks:
•	 Facilitate adaptation of recommendations and 
decisions to specific contexts
•	 Inform panels about the relative pros and cons of 
the interventions or options being considered
•	 Ensure that panels consider important criteria for 
making a decision
•	 Provide panels with a concise summary of the best 
available evidence to inform their judgments about 
each criterion
•	 Help panels structure discussion and identify rea-
sons for disagreements, making the process and 
the basis for decisions structured and transparent.
EtD frameworks assist users of recommendations by
•	 Enabling them to understand the judgments made 
by  the panel and the evidence supporting those 
 judgments
•	 Helping them to decide whether recommendations 
can and should be implemented in their own 
 settings.
Structure of the frameworks
EtD frameworks include three main sections that 
reflect the main steps in going from evidence to a deci-
sion: formulating the question, making an assessment 
of the evidence, and drawing conclusions. In this arti-
cle, we illustrate the use of an EtD framework applied 
to a recommendation about the use of a new drug 
(bedaquiline) for the treatment of multidrug-resistant 
tuberculosis (MDR-TB) (box 1, appendix 2).22 We have 
used an adapted version of a WHO recommendation as 
an example.
Formulating the question
The first step in going from evidence to a recommenda-
tion or decision is to clearly formulate the question. The 
question section of an EtD framework includes details 
of the question in a structured PICO (problem, interven-
tion, comparison, outcomes) format 23 —the perspective 
from which the options to address the question are con-
sidered—relevant subgroups, key background informa-
tion for understanding the question, and why a 
recommendation or decision is needed. In the scenario 
in box 1, the question formulated by the panel was: “In 
multiple drug-resistant tuberculosis (MDR-TB) patients, 
should bedaquiline be added to a background regimen 
based on WHO recommendations?” The panel specified 
the question details, including the population, inter-
vention, comparison, and outcomes (PICO),23  and the 
setting (MDR-TB clinics globally) (box 2). In this exam-
ple, an adaptation of a WHO recommendation,22 the 
panel took a health system perspective, taking into con-
sideration costs (and savings) to the health system and 
outcomes that might not directly affect the patients 
being treated.
The perspective that a panel takes will determine which 
economic consequences of an intervention are consid-
ered when making a recommendation or decision. Pan-
els should be explicit about this. It may also affect 
which outcomes they consider (such as availability and 
access to health services when considering a health sys-
tem perspective) and whether they look at equity, 
acceptability, and feasibility (such as when considering 
a public health or a health system  perspective).
Decisions or recommendations can differ across dif-
ferent subgroups of people. Panels should be explicit 
about which subgroups they considered, if any, ideally 
in advance. In the bedaquiline example, the panel paid 
particular attention to the subgroup of patients with 
extensive drug resistance and patients with resistance 
Box 1: Example for application of Evidence to Decision (EtD) framework
Use of bedaquiline to treat multidrug-resistant tuberculosis
“WHO	estimates	that	up	to	half	a	million	new	cases	of	multidrug-resistant	
tuberculosis	(MDR-TB)	occur	worldwide	each	year.	Current	treatment	regimens	for	
MDR-TB	present	many	challenges:	treatment	lasts	20	months	or	more,	requiring	daily	
administration	of	drugs	that	are	more	toxic,	less	effective,	and	far	more	expensive	
than	those	used	to	treat	drug-susceptible	TB.	Globally,	less	than	half	of	all	patients	
who	start	MDR-TB	therapy	are	treated	successfully.	For	the	first	time	in	over	40	years,	
a	new	TB	drug	with	a	novel	mechanism	of	action—bedaquiline—is	available,	and	was	
granted	accelerated	approval	by	the	United	States	Food	and	Drug	Administration	in	
December	2012.	There	is	considerable	interest	in	the	potential	of	this	drug	to	treat	
MDR-TB.	However,	information	about	this	new	drug	remains	limited.”22
Box 2: Evidence to Decision (EtD) framework, question section*
In multidrug-resistant tuberculosis (MDR-TB) patients, should bedaquiline be added 
to a background regimen based on WHO-recommendations?†
Population:	Multidrug-resistant	tuberculosis	(MDR-TB)	patients
Intervention:	Bedaquiline	plus	background	MDR-TB	treatment
Comparison:	Background	MDR-TB	treatment	alone
Main outcomes:	Cure	by	120	weeks,	adverse	drug	reactions	(clinical	and	biological	
serious	adverse	events),	mortality,	time	to	culture	conversion,	culture	conversion	at	
24	weeks,	acquired	resistance	to	fluoroquinolone	and	injectable	drugs
Setting:	Global,	MDR-TB	clinics
Perspective:	Population	perspective	(health	system)
Subgroups:	Patients	with	extensively	drug-resistant	(XDR)	or	pre-XDR	tuberculosis	or	
those	with	resistance	or	contraindication	to	fluoroquinolones	or	injectables
Background:
•	The	emergence	of	drug	resistance	is	a	major	threat	to	global	tuberculosis	care	and	
control.	WHO	estimates	that	around	310	000	MDR-TB	cases	(resistant	to	at	least	
rifampicin	and	isoniazid)	occurred	among	notified	tuberculosis	patients	in	2011.
•	Current	treatment	regimens	for	drug-resistant	tuberculosis	are	far	from	
satisfactory:	overall	duration	is	≥20	months,	and	it	requires	the	daily	
administration	of	drugs	that	are	more	toxic	and	less	effective	than	those	used	to	
treat	drug-susceptible	tuberculosis.
•	A	new	drug	with	a	novel	mechanism	of	action—bedaquiline—is	available,	and	
was	granted	accelerated	approval	by	the	US	Food	and	Drug	Administration	in	
December	2012.	However,	information	about	this	new	drug	remains	limited
*	Templates	used	for	EtD	frameworks	are	adapted	for	specific	types	of	decisions.	The	one	shown	here	
is	for	a	clinical	recommendation	from	a	population	perspective.
†	Adapted	from	a	WHO	guideline.22	This	should	not	be	considered	as	a	WHO	recommendation.	
An interactive	version	of	this	framework	which	includes	subgroup	information	can	be	found	at	
http://ietd.epistemonikos.org/#/frameworks/54992ce9352a502d58179c5c/question	and	at	
http://dbep.gradepro.org/profile/3879A46D-7E19-FEBA-9B96-BC2B3F996EB1.
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to or contraindications for fluoroquinolones or inject-
able medications. The rationale was that treatment 
options for these patients are limited and they may be 
more likely to accept the risks of a new drug than 
patients with uncomplicated MDR-TB.
Conflicts of interest
Intellectual and financial conflicts of interest are com-
mon and can affect judgments and recommendations or 
decisions.24-26  Guideline developers and organisations 
responsible for healthcare decisions should consider 
conflicts of interest when a panel is established.27  In 
addition, because potential conflicts of interest can 
vary across questions, panels should consider and 
report them when formulating each question. They 
should also specify actions to address these, which can 
range from simply declaring a conflict of interest to 
excluding panel members from discussions of specific 
questions or an entire guideline.25 27 28 In the bedaquiline 
example, the panel reported that all panellists declared 
either minor or no conflicts of interest (appendix 2).
Making an assessment
EtD frameworks make explicit the criteria that are used 
to assess interventions or options, the judgments made 
by the panel for each criterion, and the research evi-
dence and additional considerations used to inform 
each judgment. Research evidence refers to facts (actual 
or asserted) used to inform the panel’s judgments that 
are derived from studies that used systematic and 
explicit methods. Additional considerations include 
other evidence, such as routinely collected data, 
assumptions, and logic used to make a judgment. Pan-
els may make different judgments for one or more sub-
groups (such as patients who are older or who have 
more severe disease) in relation to some or all of the 
criteria. When relevant, they may also report additional 
details, such as dissenting views of panel members or 
the results of voting on judgments where there was dis-
agreement. The assessment of the different criteria 
made by the panel in the bedaquiline example are 
available in appendix 2 (an interactive version is avail-
able at http://ietd.epistemonikos.org/#/frame-
works/54992ce9352a502d58179c5c/question and at 
http://dbep.gradepro.org/profile/3879A46D-7E19-
FEBA-9B96-BC2B3F996EB1.
Different types of decisions and different perspec-
tives require different considerations. Consequently, we 
suggest specific sets of criteria for clinical recommenda-
tions from an individual patient perspective, clinical 
recommendations from a population perspective, cov-
erage decisions, recommendations and decisions about 
tests, and health system or public health recommenda-
tions and decisions (table 1).
Although there are differences in the operationalisa-
tion of the criteria for different types of decisions, most 
of the criteria are similar, as can be seen in table 1, 
which shows the criteria for five types of decisions. All 
five sets of criteria include questions about whether the 
problem is a priority, the magnitude of the desirable 
and undesirable effects, the certainty of the evidence, 
consideration of how patients (or others affected, such 
as carers) value the main outcomes, the balance 
between desirable and undesirable effects, resource 
use, acceptability, and feasibility. All of the frameworks 
that take a population perspective also include consid-
eration of impacts on equity.
For questions regarding tests, when there is no direct 
evidence from randomised trials or observational stud-
ies of the impact of alternative testing strategies on 
important outcomes, additional criteria are required.29 
This includes consideration of test accuracy and the 
certainty of the different types of evidence used to 
inform judgments about the desirable and undesirable 
effects of a test (including direct effects, such as adverse 
effects from invasive tests, and indirect effects, result-
ing from management decisions based on the test 
results).
Organisations may want to tailor the criteria that they 
use. For example, guideline developers may have 
assessed the priority of problems before making recom-
mendations and therefore might elect not to include the 
priority of the problem as a criterion. Conversely, some 
organisations, due to their mandate, might elect to con-
sider a factor separately as an additional criterion 
rather than as a detailed judgment for a broader crite-
rion. For example, autonomy and other ethical consid-
erations are included as detailed judgments under 
acceptability in EtD frameworks. However, an organisa-
tion might elect to consider autonomy as a separate cri-
terion, rather than as a detailed judgment under 
acceptability. Table 2 shows other criteria that we have 
incorporated as detailed judgments, which some organ-
isations might want to consider as separate criteria.
A key feature of the EtD frameworks, like other 
GRADE-DECIDE presentations,32  is that they are lay-
ered; that is, they present key messages in the top layer 
with links to more detailed information. For example, 
the frameworks include concise summaries of the most 
important research evidence for each criterion (appen-
dix 2). Typically, this is summarised in a table or a para-
graph of text. From the framework, it is possible to link 
to information that is more detailed - for example, an 
evidence profile 15 or an interactive Summary of Find-
ings table (http://isof.epistemonikos.org/#/find-
ing/543952e4f30d0c47cb1a1495) and from there to even 
more detailed information, such as a systematic review. 
This helps to structure discussions, ensure that there is 
a shared understanding of the key findings of the 
research that informs each judgment, and avoids prob-
lems that sometimes arise when panel members receive 
large piles of documents without concise summaries. It 
also makes it easier for panel members and users of rec-
ommendations, when needed, to dig deeper into the 
supporting evidence.
Drawing conclusions
Drawing conclusions begins with the panel reviewing 
the judgments they have made for all of the criteria in 
their assessment and considering the implications of 
those judgments for the recommendation or decision. 
Based on their assessment, the panel draws  conclusions 
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about the strength of recommendation or type of deci-
sion; for example, a strong or weak (sometimes called 
conditional, discretionary, or qualified) recommenda-
tion for or against an intervention or option. In addi-
tion, the panel states the recommendation or decision 
in a concise, clear and actionable manner,18 and pro-
vides the justification for their recommendation or deci-
sion. The conclusions also include relevant 
considerations about subgroups, implementation, 
monitoring and evaluation, and research priorities (see 
box 3 for the conclusions reached in the bedaquiline 
example).
Guideline panels may be reluctant to make a recom-
mendation for or against an intervention or option. 
Table 2 | Detailed judgments in Evidence to Decision (EtD) frameworks
Criterion Detailed judgments
Is the problem a priority?* •  Are the consequences of the problem serious (that is, severe or important in terms of the potential benefits or 
savings)?
•  Is the problem urgent? [Not relevant for coverage decisions]
•  Is it a recognised priority (such as based on a political or policy decision)? [Not relevant when an individual 
patient perspective is taken]
How substantial are the desirable anticipated effects? •  Judgments for each outcome for which there is a desirable effect
How substantial are the undesirable anticipated effects? •  Judgments for each outcome for which there is an undesirable effect
What is the overall certainty of the evidence of effects? •  See GRADE guidance regarding detailed judgments about the quality of evidence or certainty in estimates of 
effects3031
Is there important uncertainty about or variability in how 
much people value the main outcomes?
•  Is there important uncertainty about how much people value each of the main outcomes?
•  Is there important variability in how much people value each of the main outcomes? [Not relevant for coverage 
decisions]
Do the desirable effects outweigh the undesirable 
effects?
•  Judgments regarding each of the four preceding criteria
•  To what extent do the following considerations influence the balance between the desirable and undesirable 
effects:
 -  How much less people value outcomes that are in the future compared to outcomes that occur now (their 
discount rates)?
 -  People’s attitudes towards undesirable effects (how risk averse they are)?
 -  People’s attitudes towards desirable effects (how risk seeking they are)?
How large are the resource requirements?† •  How large is the difference in each item of resource use for which fewer resources are required?
•  How large is the difference in each item of resource use for which more resources are required?
What is the certainty of the evidence of resource 
requirements?†
•  Have all-important items of resource use that may differ between the options being considered been 
identified?
•  How certain is the evidence of differences in resource use between the options being considered (see GRADE 
guidance regarding detailed judgments about the quality of evidence or certainty in estimates)?
•  How certain is the cost of the items of resource use that differ between the options being considered?
•  Is there important variability in the cost of the items of resource use that differ between the options being 
considered?
Are the net benefits worth the incremental cost?* •  Judgments regarding each of the six preceding criteria
•  Is the cost effectiveness ratio sensitive to one-way sensitivity analyses?
•  Is the cost effectiveness ratio sensitive to multivariable sensitivity analysis?
•  Is the economic evaluation on which the cost effectiveness estimate is based reliable?
•  Is the economic evaluation on which the cost effectiveness estimate is based applicable to the setting(s) of 
interest?
What would be the impact on health equity?*† •  Are there groups or settings that might be disadvantaged in relation to the problem or interventions (options) 
that are considered?
•  Are there plausible reasons for anticipating differences in the relative effectiveness of the intervention (option) 
for disadvantaged groups or settings?
•  Are there different baseline conditions across groups or settings that affect the absolute effectiveness of the 
intervention or the importance of the problem for disadvantaged groups or settings?
•  Are there important considerations that should be made when implementing the intervention (option) in order 
to ensure that inequities are reduced, if possible, and that they are not increased?
Is the intervention/option acceptable to key 
stakeholders?*
•  Are there key stakeholders who would not accept the distribution of the benefits, harms and costs?
•  Are there key stakeholders who would not accept the costs or undesirable effects in the short term for 
desirable effects (benefits) in the future?
•  Are there key stakeholders who would not agree with the importance (value) attached to the desirable or 
undesirable effects (because of how they might be affected personally or because of their perceptions of the 
relative importance of the effects for others)?
•  Would the intervention adversely affect people’s autonomy?
•  Are there key stakeholders who would disapprove of the intervention morally, for reasons other than its effects 
on people’s autonomy (such as in regard to ethical principles such as no maleficence, beneficence, or justice)?
Is the intervention feasible to implement?* For decisions other than coverage decisions:
 •  Is the intervention or option sustainable?
 •  Are there important barriers that are likely to limit the feasibility of implementing the intervention (option) or 
require consideration when implementing it?3031
For coverage decisions:
 •  Is coverage of the intervention sustainable?
 •  Is it feasible to ensure appropriate use for approved indications?
 •  Is inappropriate use (indications that are not approved) an important concern?
 •  Is access to the intervention an important concern?
 •  Are there important legal or bureaucratic or legal constraints that that make it difficult or impossible to cover 
the intervention?
*The certainty of the evidence could be considered as a detailed judgement for these criteria.
†These criteria are not included when an individual patient perspective is taken.
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Panels should not fail to make a recommendation sim-
ply because different people would make different 
choices. Indeed, that is a defining feature when mak-
ing a weak recommendation. However, one reason for 
not recommending for or against an intervention or 
option is that the pros and cons of the intervention or 
option and the comparison are so closely balanced 
that the panel is not prepared to make a weak recom-
mendation in one direction or the other. Another pos-
sible reason is that there is so much uncertainty that 
the panel concludes that a recommendation either for 
or against the intervention or option would be 
 speculative.17-19
The types of recommendations or decisions that are 
appropriate vary. For example, strong and weak recom-
mendations are appropriate for clinical recommenda-
tions and these different types of recommendations 
have clear implications for clinicians and patients.17-19 
The WHO panel, for example, developed an interim rec-
ommendation regarding bedaquiline that was condi-
tional because the certainty of the evidence was very 
low and because it is recommended only under specific 
conditions (box 3).
It is not, however, possible to make a strong or weak 
coverage, health system, or public health decision. For 
example, an intervention is either covered or it is not, 
although there can be caveats to coverage. Types of cov-
erage decisions that are possible include not covering 
an intervention, coverage only in the context of 
research,33 covering it with price negotiation, restricted 
coverage, and full coverage.
The justification for a recommendation or decision 
should flow from the judgments that the panel made in 
relation to the criteria used in the assessment. A 
detailed justification can elaborate on the panel’s 
thinking for the key criteria that drove their recommen-
dation or decision, as illustrated with the bedaquiline 
example (an adapted version of a WHO recommenda-
tion) in box 3. The panel’s conclusions about subgroup 
considerations should specify which subgroups the 
panel considered and how those considerations 
affected their recommendation. If the panel’s judg-
ments (and the research evidence or additional consid-
erations that informed those judgments) and their 
conclusions for a subgroup are very different from the 
overall assessment, the panel can elect to present a sep-
arate EtD framework for the subgroup.
Conclusions about implementation considerations 
should specify key concerns about the feasibility and 
acceptability of the intervention and strategies to 
address those concerns, as well as any important infor-
mation about how to implement the intervention, par-
ticularly for complex interventions. Conclusions about 
monitoring and evaluation should include suggestions 
for which, if any, indicators should be monitored and 
any evaluation that is needed in connection with imple-
menting the recommendation or decision. This is par-
ticularly relevant for health system and public health 
decisions and recommendations. Finally, having 
reviewed and assessed the evidence, panels should 
identify research priorities to address any important (
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uncertainties or gaps in the research evidence that 
informed their judgments.
How are EtD frameworks prepared and used by panels 
and users of recommendations
Technical teams or others with relevant expertise 
should generally prepare EtD frameworks. Expertise 
should typically include an understanding of appropri-
ate systematic review methods,34  the GRADE system,13 14 
and the clinical, health system, or public health topic. 
The GRADEPro Guideline Development Tool (GRA-
DEPro GDT) (www.gradepro.org), the interactive EtD 
(http://ietd.epistemonikos.org/), and the interactive 
Summary of Findings (iSoF; http://isof.epistemonikos.
org/) are free, web based software solutions for prepar-
ing and using interactive EtD frameworks. The iEtD and 
iSoF are also integrated in other alternative authoring 
and publication tools such as MAGIC (Making GRADE 
the Irresistible Choice; www.magicapp.org). These tools 
facilitate collaborative preparation and management of 
EtD frameworks by technical teams and the use of EtD 
frameworks by panels. They also support the dissemi-
nation of information derived from the frameworks to 
target audiences, including preparation of presenta-
tions tailored to clinicians, patients and the public, or 
policy makers in different formats. GRADEpro also has 
an all-in-one web solution for managing, summarising, 
and presenting information for healthcare decision 
making and developing guidelines. As part of this func-
tionality, GRADEPro GDT supports creating evidence 
profiles and Summary of Findings (SoF) tables,15 and it 
facilitates the development of clinical practice guide-
lines. GRADEpro also contains a growing database of 
evidence profiles and evidence to decision frameworks 
(http://dbep.gradepro.org/search).
EtD frameworks can also be used by guideline devel-
opers to adapt recommendations to specific contexts or 
can be used by decision makers deciding whether to 
implement a recommendation in their setting. “Recom-
mendation to decision (RtD)” presentations can facili-
tate this process, as illustrated for the bedaquiline 
example in appendix 3 (an adapted version of a WHO 
recommendation). These presentations can be gener-
ated by the iEtD. Clinicians and other users of recom-
mendations can use the frameworks to systematically 
review recommendations and decide whether they are 
applicable to their setting or to particular patients.
Final remarks and future developments
Over the past 15 years the GRADE Working Group has 
established criteria for moving from evidence to rec-
ommendations. These criteria have been applied in 
numerous clinical and public health guidelines, and 
their use has increased transparency in guidelines 
and provided a structured approach for determining 
the direction and strength of a recommendation. EtD 
frameworks are an evolution of this approach to mak-
ing recommendations.
Advantages of EtD frameworks compared with less 
structured approaches used in guideline development 
and decision making include:
•	 Rigorous development by a wide international multi-
disciplinary group
•	 Transparent process for moving from evidence to rec-
ommendations or decisions
•	 Explicit consideration of how much outcomes are 
valued by those affected by a decision
•	 Use of a layered approach by panels and in dissemi-
nating recommendations or decisions.
The EtD frameworks differ from the earlier versions of 
GRADE Evidence to Recommendation tables17-19  in sev-
eral ways. They incorporate new criteria and require 
more explicit and structured summaries of evidence to 
address each criterion, beyond summaries of findings 
for the effects of interventions.14 They address coverage, 
health system, and public health decisions, as well as 
recommendations, and they facilitate decision making 
based on recommendations. They require panels to 
specify the perspective they are taking and differences 
in their judgments for specific criteria for relevant sub-
groups. They provide a more detailed structure that can 
help to facilitate panel discussions, make discussions 
more efficient, and clarify the research evidence used to 
inform discussions; and they help ensure that recom-
mendations and decisions flow from judgments about 
relevant criteria and make the basis for recommenda-
tions more transparent.
A potential limitation of EtD frameworks is their 
increased complexity compared with the previous 
GRADE Evidence to Recommendation tables. Because 
healthcare decisions are complex, any system for mov-
ing from evidence to decisions requires a balance 
between simplicity and full transparent consideration 
of all the important factors. Although EtD frameworks 
are more complex than the previous approach sug-
gested by the GRADE Working Group for making judg-
ments about the strength of recommendations,17-19 they 
add clarity and make the judgments underlying a deci-
sion more explicit. Moreover, we have found that, once 
the question has been formulated and evidence 
searched for and summarised, the process of reaching 
decisions using EtD frameworks does not add substan-
tial amounts of time to the decision making process. 
Nevertheless, as with the use of other methods, master-
ing the use of EtD frameworks requires familiarisation 
and practice.
Ideally, research evidence should be used to inform 
judgments about each criterion in EtD frameworks. 
However, often research evidence will be lacking or 
organisations will have limited resources to find and 
systematically review all of the relevant evidence. EtD 
frameworks explicitly show what, if any, research evi-
dence was used to inform each judgment and, if no 
research evidence was available, what considerations 
were made. Organisations can tailor the criteria that 
they use and might elect not to use some criteria. How-
ever, all of the criteria included in the EtD frameworks 
can sometimes be critical for a decision. Therefore, we 
suggest that organisations wanting to reduce the num-
ber of criteria, should first consider the implications of 
doing so. For example, if a guideline developer elects 
not to include criteria related to resource use, it is then 
the bmj | BMJ 2016;353:i2016 | doi: 10.1136/bmj.i2016
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either making implicit judgments about resource use or 
leaving it up to users of their guidelines to consider 
resource use when deciding whether to adhere to their 
recommendations.
We have put substantial effort into both identifying a 
comprehensive set of criteria and making the frame-
works as simple as possible. As with all aspects of the 
GRADE system, we will continue to monitor and evalu-
ate the use of EtD frameworks in practice and, if needed, 
refine the criteria that are included in each of the frame-
works or other aspects of the frameworks.
The use of multiple criteria in making healthcare rec-
ommendations or decisions, and the use of evidence 
that goes beyond evidence of effectiveness and cost 
effectiveness are not new.1-4 35-38  Some have argued for 
the use of multiple criteria decision analysis (MCDA) 
(using mathematical models) in health technology 
assessment and coverage decisions.37-39  However, these 
models have rarely been used. The advantages and dis-
advantages of using MCDA compared with EtD frame-
works are similar to the advantages and disadvantages 
of using a balance sheet approach compared with an 
economic evaluation.39 It might sometimes be desirable 
to use both, but few organisations are likely to have the 
resources to undertake MCDA, and there are many 
uncertainties regarding MCDA models and their role in 
informing these types of decisions.
EtD frameworks provide an approach to structured 
reflection that can help those making recommenda-
tions or decisions to be more systematic and explicit 
about the judgments that they make, the evidence used 
to inform each of those judgments, additional consider-
ations, and the basis for their recommendations or deci-
sions. For users of recommendations and those affected 
by decisions, EtD frameworks can help to ensure the 
trustworthiness of those recommendations or deci-
sions, enable them to appraise the basis for recommen-
dations or decisions, and facilitate adaptation of 
recommendations or decisions to their own contexts.
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